Modality
Bispecific Ab
MOA
PD-L1i
Target
IL-13
Pathway
Fibrosis
MyelofibrosisAtopic DermPV
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
Jul 2020
→ Jun 2029
Phase 1Current
NCT05645984
2,595 pts·PV
2020-07→2029-06·Recruiting
NCT06356178
835 pts·Myelofibrosis
2021-03→2027-08·Recruiting
3,430 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-101.4y awayInterim· Myelofibrosis
2029-06-153.2y awayInterim· PV
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2027-08-10 · 1.4y away
Myelofibrosis
Interim
2029-06-15 · 3.2y away
PV
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05645984 | Phase 1 | PV | Recruiting | 2595 | LiverFat |
| NCT06356178 | Phase 1 | Myelofibrosis | Recruiting | 835 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |